Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Deferred Revenue (2016 - 2023)

Theravance Biopharma (TBPH) has disclosed Current Deferred Revenue for 11 consecutive years, with $24000.0 as the latest value for Q3 2023.

  • Quarterly Current Deferred Revenue changed 0.0% to $24000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $24000.0 through Sep 2023, changed 0.0% year-over-year, with the annual reading at $24000.0 for FY2022, 75.51% down from the prior year.
  • Current Deferred Revenue for Q3 2023 was $24000.0 at Theravance Biopharma, roughly flat from $24000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $43.3 million in Q2 2019, with the low at $24000.0 in Q2 2022.
  • Average Current Deferred Revenue over 5 years is $12.9 million, with a median of $5.7 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue plummeted 99.58% in 2022, then changed 0.0% in 2023.
  • Over 5 years, Current Deferred Revenue stood at $31.6 million in 2019, then tumbled by 63.51% to $11.5 million in 2020, then plummeted by 99.15% to $98000.0 in 2021, then plummeted by 75.51% to $24000.0 in 2022, then changed by 0.0% to $24000.0 in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $24000.0, $24000.0, and $24000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.